Ultrasound vendor Acuson has been awarded an exclusive contract to supply radiology and ultrasound systems to Tenet Healthcare. The agreement with BuyPower, the national group-purchasing organization for Tenet, designates Mountain View, CA-based Acuson
Ultrasound vendor Acuson has been awarded an exclusive contract to supply radiology and ultrasound systems to Tenet Healthcare. The agreement with BuyPower, the national group-purchasing organization for Tenet, designates Mountain View, CA-based Acuson as the sole provider of radiology and vascular ultrasound equipment to Tenets 113 acute-care hospitals through May of this year and permits all BuyPower members to purchase ultrasound equipment from Acuson under the same terms. BuyPower currently acts as the purchasing agent for 510 acute-care hospitals, 531 nonacute-care hospitals, and 45,000 physicians nationwide.
The deal continues the business-boosting momentum the company began with the new year: In January, Acuson completed its purchase of Ecton, a developer of a miniaturized echocardiography technology, which it purchased for approximately $17 million in shares and $4 million in cash (SCAN 1/12/00). Acuson reported 1999 revenues and net income (end-December) of $476 million and $20.6 million, respectively, compared with 1998s $455 million and $20.8 million.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.